captopril has been researched along with Mucocutaneous Lymph Node Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farhang, S; Javadzadegan, H; Mehdizadeh Baghbani, J | 1 |
| Inoue, N; Jin, D; Kajiura, M; Kawamura, N; Miyazaki, M; Okamura, N; Okumura, K; Takai, S; Tamai, H; Yoshikawa, S | 1 |
2 other study(ies) available for captopril and Mucocutaneous Lymph Node Syndrome
| Article | Year |
|---|---|
Acute myocardial infarction as the first manifestation of the incomplete Kawasaki disease in a young male.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomarkers; Captopril; Child; Coronary Angiography; Diagnosis, Differential; Drug Therapy, Combination; Echocardiography; Electrocardiography; Humans; Male; Mucocutaneous Lymph Node Syndrome; Myocardial Infarction; Platelet Aggregation Inhibitors; Warfarin | 2009 |
Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Infant; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mucocutaneous Lymph Node Syndrome; Peptidyl-Dipeptidase A | 2010 |